Ipilimumab/Nivolumab in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants
JAMA Oncol 2022 Apr 21;[EPub Ahead of Print], G Terrero, J Datta, J Dennison, DA Sussman, I Lohse, NB Merchant, PJ HoseinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.